• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    11/22/22 12:31:49 PM ET
    $ACHV
    $CING
    $COSM
    $CYCN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACHV alert in real time by email

    Gainers

    • Palisade Bio (NASDAQ:PALI) shares moved upwards by 127.8% to $5.04 during Tuesday's regular session. As of 12:30 EST, Palisade Bio's stock is trading at a volume of 44.9 million, which is 28949.4% of its average full-day volume over the last 100 days. The company's market cap stands at $7.1 million.
    • Cosmos Holdings (NASDAQ:COSM) shares moved upwards by 46.17% to $0.26. As of 12:30 EST, Cosmos Holdings's stock is trading at a volume of 222.4 million, which is 1495.2% of its average full-day volume over the last 100 days. The company's market cap stands at $21.4 million.
    • Cingulate (NASDAQ:CING) shares moved upwards by 32.21% to $0.91. The current volume of 357.0K shares is 490.3% of Cingulate's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $10.3 million.
    • Cyclerion Therapeutics (NASDAQ:CYCN) shares increased by 23.17% to $0.69. Cyclerion Therapeutics's stock is trading at a volume of 407.7K shares as of 12:30 EST. This is 197.9% of its average full-day volume over the last 100 days. The company's market cap stands at $30.0 million.
    • Meihua Intl Medical Techs (NASDAQ:MHUA) shares rose 19.28% to $10.55. The market value of their outstanding shares is at $252.5 million.
    • Achieve Life Sciences (NASDAQ:ACHV) shares increased by 17.96% to $2.95. Trading volume for this security as of 12:30 EST is 303.0K, which is 584.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $28.6 million.

    Losers

    • Macrogenics (NASDAQ:MGNX) shares fell 19.4% to $5.13 during Tuesday's regular session. Trading volume for Macrogenics's stock is 1.0 million as of 12:30 EST. This is 124.5% of its average full-day volume over the last 100 days. The company's market cap stands at $315.6 million.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock decreased by 17.01% to $2.05. As of 12:30 EST, this security is trading at a volume of 310.3K shares, making up 60.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $19.5 million.
    • Graybug Vision (NASDAQ:GRAY) stock fell 15.35% to $0.8. Graybug Vision's stock is trading at a volume of 590.5K shares as of 12:30 EST. This is 735.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $17.2 million.
    • Mesa Laboratories (NASDAQ:MLAB) stock decreased by 13.46% to $159.37. The current volume of 80.3K shares is 114.7% of Mesa Laboratories's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $850.5 million.
    • Scopus BioPharma (NASDAQ:SCPS) stock declined by 13.25% to $0.21. The current volume of 338.1K shares is 95.2% of Scopus BioPharma's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $4.4 million. The company's, Q3 earnings came out yesterday.
    • Sharps Technology (NASDAQ:STSS) shares declined by 12.72% to $1.03. The company's market cap stands at $9.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACHV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHV
    $CING
    $COSM
    $CYCN

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Achieve Life Sciences Inc.
    $ACHV
    11/25/2025$19.00Mkt Outperform
    Citizens JMP
    MacroGenics Inc.
    $MGNX
    9/17/2025$3.00Overweight
    Barclays
    Achieve Life Sciences Inc.
    $ACHV
    8/21/2025$12.00Buy
    H.C. Wainwright
    Mesa Laboratories Inc.
    $MLAB
    8/7/2025$67.00Underweight → Equal Weight
    Wells Fargo
    Cingulate Inc.
    $CING
    1/10/2025$12.00Buy
    ROTH MKM
    More analyst ratings

    $ACHV
    $CING
    $COSM
    $CYCN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and CSO Silva Raul R. was granted 4,526 shares and covered exercise/tax liability with 1,828 shares, increasing direct ownership by 139% to 4,645 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/11/26 8:13:31 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CLO and CCO Patel Nilay Dahyabhai was granted 5,475 shares and covered exercise/tax liability with 2,086 shares (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/11/26 8:13:27 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. was granted 6,862 shares and covered exercise/tax liability with 2,959 shares, increasing direct ownership by 2,256% to 4,076 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/11/26 8:13:30 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHV
    $CING
    $COSM
    $CYCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Palisade Bio with a new price target

    Piper Sandler initiated coverage of Palisade Bio with a rating of Overweight and set a new price target of $25.00

    12/29/25 7:10:24 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $CING
    $COSM
    $CYCN
    SEC Filings

    View All

    $ACHV
    $CING
    $COSM
    $CYCN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mesa Laboratories Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)

    3/9/26 5:02:29 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    MacroGenics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MACROGENICS INC (0001125345) (Filer)

    3/9/26 4:12:10 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by MacroGenics Inc.

    10-K - MACROGENICS INC (0001125345) (Filer)

    3/9/26 4:10:34 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ladiwala Shiraz Shabanali bought $252,805 worth of shares (3,500 units at $72.23), increasing direct ownership by 70% to 8,523 units (SEC Form 4)

    4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)

    3/10/26 5:43:24 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    Director Capone Mark Christopher bought $99,331 worth of shares (1,301 units at $76.35), increasing direct ownership by 61% to 3,429 units (SEC Form 4)

    4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)

    3/10/26 3:46:59 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    Director Tripeny R Tony bought $99,940 worth of shares (1,315 units at $76.00), increasing direct ownership by 32% to 5,398 units (SEC Form 4)

    4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)

    3/10/26 3:39:49 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    $ACHV
    $CING
    $COSM
    $CYCN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000

    CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the purchase of $600,000 of Bitcoin as part of its ongoing digital assets treasury initiative. Following this purchase, Cosmos Health's total investment in digital assets has reached $3.1 million, reflecting the combined value of its holdings in Bitcoin and Ethereum. Greg Siokas, CEO of Cosmos Health, stated: "We continue to view select digital assets as an attractive asset class with strong upside potential. Our growing position in Bitcoin and Ethereum reflects a disciplined treasury strategy design

    3/11/26 1:45:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000

    CHICAGO, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has entered into a Letter of Intent ("LOI"), through its wholly owned subsidiary CosmoFarm S.A. ("CosmoFarm"), with respect to the acquisition of an extensive pharmacy distribution network from an established pharmaceutical company serving the Greek market for almost 40 years. The term of the LOI is ninety (90) days from March 6, 2026. The network currently generates approximately €10 million (approximately $11.5 million based on the prevailing EUR/USD exchange rate) in annual gross reve

    3/10/26 9:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO

    LAKEWOOD, Colo., March 09, 2026 (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or "the Company"), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens will step down as President and CEO on April 12, 2026, and will enable a smooth leadership transition. "Gary has served as Mesa's CEO since 2017, leading Mesa through a period of significant growth, expansion into new markets, the maturation of the company's foundation, and the implementation of The Mesa Way business system," said John Sullivan, Chair of the Board. "We are grateful for his leadership and wish him continued success." T

    3/9/26 4:30:00 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    $ACHV
    $CING
    $COSM
    $CYCN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MARGENZA issued to MACROGENICS INC

    Submission status for MACROGENICS INC's drug MARGENZA (SUPPL-5) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 05/25/2023. Application Category: BLA, Application Number: 761150, Application Classification:

    5/29/23 4:45:45 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MARGENZA

    Submission status for MACROGENICS INC's drug MARGENZA (ORIG-1) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 12/16/2020. Application Category: BLA, Application Number: 761150, Application Classification:

    12/20/20 4:31:01 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHV
    $CING
    $COSM
    $CYCN
    Leadership Updates

    Live Leadership Updates

    View All

    Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO

    LAKEWOOD, Colo., March 09, 2026 (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or "the Company"), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens will step down as President and CEO on April 12, 2026, and will enable a smooth leadership transition. "Gary has served as Mesa's CEO since 2017, leading Mesa through a period of significant growth, expansion into new markets, the maturation of the company's foundation, and the implementation of The Mesa Way business system," said John Sullivan, Chair of the Board. "We are grateful for his leadership and wish him continued success." T

    3/9/26 4:30:00 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $CING
    $COSM
    $CYCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Meihua International Medical Technologies Co. Ltd.

    SC 13G - Meihua International Medical Technologies Co., Ltd. (0001835615) (Subject)

    11/14/24 6:08:55 PM ET
    $MHUA
    Medical/Dental Instruments
    Health Care

    $ACHV
    $CING
    $COSM
    $CYCN
    Financials

    Live finance-specific insights

    View All

    MESA LABS DECLARES QUARTERLY DIVIDEND

    LAKEWOOD, Colo., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increa

    1/7/26 5:00:00 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

    SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its third quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Thursday, November 6, 2025, at 8:30 AM EST. To access the webcast, please use the following link: 3Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 888-396-8049 (U.S. & Canada) or 416-764-8646 (International) and

    10/29/25 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    MESA LABS DECLARES QUARTERLY DIVIDEND

    Lakewood, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2025, to shareholders of record at the close of business on November 28, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in

    10/3/25 11:01:27 AM ET
    $MLAB
    Industrial Machinery/Components
    Industrials